tbuckley/cabot-search huggingface dataset:
Abstract 16121: The Decade of Change: Survival Following Out-of-hospital Cardiac Arrest in Teaching versus Nonteaching Hospitals in the United States: 2000-2012
Authors: Shaker M Eid, Aiham Albaeni, Bolanle Akinyele, Lekshmi N Raghavakurup, Nisha Chandra-Strobos
Journal: Circulation (2015)

Background: All hospitals, regardless of teaching status, need to provide care for OHCA patients. Whether outcomes differ in teaching vs nonteaching hospitals is unknown and was examined in this study. Methods: Using the National Inpatient Sample database, we selected adults ≥18 years old admitted with a principle diagnosis of non-traumatic OHCA (ICD-9 CM codes 427.5 &amp; 427.41) between 2000 and 2012. Patients were stratified to teaching (THs) or nonteaching hospitals (NTHs). The association of hospital teaching status with length of stay, total charges/case, survival to discharge, and survival with good neurologic outcome was assessed by multivariate logistic regression or generalized linear regression models, adjusting for patient and hospital-level characteristics. Results: Of 186,483 admitted patients, 86,053 (46.15%) were treated at teaching hospitals during the study period. Overall OHCA incidence in the United States was 3.86 per 10,000 hospital admissions. Patients at teaching hospitals were more often younger, more likely to have VF, and less likely to be Caucasian [all p &lt; 0.001] but with a similar comorbidity burden. Mean length of stay and total charges were higher in teaching hospitals (5 vs. 4 days, p&lt;0.01 &amp; $72,436 vs. $52,917, p&lt;0.01). Risk-adjusted survival and survival with good neurologic outcome were significantly better in THs as compared to NTHs (odds ratio, 1.06 ; 95% CI 1.02 – 1.14 &amp; 1.19 ; 95% CI 1.09 – 1.29 respectively). Despite a significant increase in OHCA survival at NTHs between 2000 and 2012 ( P trend &lt;0.01), OHCA survival rate at THs remained higher without any change in trend ( P trend =0.07) during the study period. Conclusion: For OHCA patients in the US, survival has been consistently higher in teaching hospitals. However, a dramatic improvement in survival has been realized in nonteaching hospitals over the last 12 years with lesser healthcare expenditure when compared to teaching hospitals; this phenomenon is worthy of further study.
INFLUENCE OF POST-IMPLANTATION NON-FATAL ADVERSE EVENTS ON CONDITIONAL SURVIVAL IN PATIENTS WITH DURABLE LEFT VENTRICULAR ASSIST DEVICE SUPPORT FOR DESTINATION THERAPY
Authors: Katherine Clare Michelis, Lin Zhong, Matthias Peltz, Ambarish Pandey, James Young, Wai Hong Wilson Tang, Anand Rohatgi, Mark H. Drazner, Justin Lee Grodin
Journal: Journal of the American College of Cardiology (2020)
HIGH UTILIZATION RATE OF IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS AMONG VICTIMS OF OUT OF HOSPITAL PREMATURE NATURAL DEATH IN A LARGE RURAL COMMUNITY
Authors: Suvwe Eboh, Victor Okunrintemi, Ouassim Derbal, Sharidan Maxwell Hill, Yuxuan Mao, Elisabeth Lee, Aditi Naniwadekar, Irion Pursell, Samuel Sears, John Mounsey
Journal: Journal of the American College of Cardiology (2020)
SHORT TERM EFFECT OF SELEXIPAG IN COMPARISON TO PROSTACYCLIN ANALOGUES IN PULMONARY ARTERIAL HYPERTENSION PATIENTS STARTED ON DOUBLE-COMBINATION THERAPY WITH ERA AND PDE-5 INHIBITORS
Authors: Fabio Dardi, Massimiliano Palazzini, Elisa Zuffa, Alessandro De Lorenzis, Daniele Guarino, Filippo Pasca, Ilenia Magnani, Mariangela Rotunno, Alberto Ballerini, Alessandra Manes, Nazzareno Galié
Journal: Journal of the American College of Cardiology (2020)
Impact of gemcitabine (G) on the activity of first-line chemotherapy in non-small cell lung cancer (NSCLC): A meta-analysis
Authors: G. L. Pappagallo, O. Belvedere, O. Vinante, F. Grossi
Journal: Journal of Clinical Oncology (2006)

7138 Background: A two-drug platinum-based regimen in which cisplatin or carboplatin is combined with a third-generation agent (i.e. paclitaxel, vinorelbine, docetaxel, or G) is the standard first-line treatment for NSCLC patients with good performance status. Encouraging results have recently been reported for nonplatinum regimens composed of two third-generation drugs. Methods: To assess the impact of G on the activity of first-line chemotherapy in NSCLC, we carried out a meta-analysis on data from 4,362 NSCLC patients who were enrolled in 11 randomized trials comparing a G-containing vs. G-free new generation regimens. We constructed 2x2 tables using response to treatment data. For trials with more than one eligible G-free comparator arm, individual comparisons between the G-based treatment arms and each of the comparator arms were analyzed. A general variance-based method was used to estimate the pooled odds ratio (OR) and 95% confidence interval (CI). We assessed for heterogeneity among the trials based on standard methods. Results: Sixteen comparisons contributed to this analysis. G-containing regimens included: G+cisplatin (894), G+docetaxel (565), G+paclitaxel (200 patients), G+vinorelbine (157), G+carboplatin (49). G-free regimens included: vinorelbine+cisplatin (866), carboplatin+paclitaxel (539), docetaxel+cisplatin (494), cisplatin+paclitaxel (439), vinorelbine+carboplatin (159). Comparing G-containing vs. G-free regimens, the OR for progression was 0.867 (CI 95% 0.770–0.977; p = 0.019), with heterogeneity chi-square 11.639 (p = 0.71). No significant difference was observed for complete (OR 0.909, CI 95% 0.556–1.487; P = 0.707) and overall (complete + partial) response (OR 0.987, CI 95% 0.881–1.106; P = 0.819). Conclusions: These data demonstrate that the progression of disease is more likely in patients treated with G-free doublets. Further analyses are required to address whether disease control (objective response + stable disease) is associated with a survival benefit and may therefore be used as a surrogate end point for survival in chemotherapy trials of NSCLC. No significant financial relationships to disclose.
COMPARING EFFICACY AND SAFETY OF VERAPAMIL VERSUS DILTIAZEM IN ATRIAL FIBRILLATION AND FLUTTER WITH RAPID VENTRICULAR RESPONSE
Authors: Ankita Aggarwal, Anubhav Jain, Kristen Hughes, Manishkumar Patel, Mulham Hamdon, Sarwan Kumar
Journal: Journal of the American College of Cardiology (2020)
INTRACORONARY IMAGING-GUIDED DISCONTINUATION OF DUAL ANTIPLATELET THERAPY IN STENTED PATIENTS REQUIRING EXPEDITED CANCER TREATMENT
Authors: Moez Aziz, Dinu Balanescu, Teodora Donisan, Juhee Song, Nicolas Palaskas, Juan C. Lopez-Mattei, Peter Y. Kim, Mehmet Cilingiroglu, Joerg Herrmann, Konstantinos Marmagkiolis, Anita Deswal, Cezar Iliescu
Journal: Journal of the American College of Cardiology (2020)
BASELINE GLOBAL LEFT VENTRICULAR MYOCARDIAL WORK INDEX CAN PREDICT IMPROVEMENT IN EJECTION FRACTION IN PATIENTS WITH CLASSICAL LOW FLOW LOW GRADIENT AORTIC STENOSIS UNDERGOING TAVR
Authors: AASHISH GUPTA, Rikin Kadakia, Harmanjot Khaira, Sergey Kachur, Mohanad Hasan, Thomas Middour, Yvonne Gilliland, Michael Cash, Stephen Ramee, Jose David Tafur Soto, Daniel Morin, SALIMA QAMRUDDIN
Journal: Journal of the American College of Cardiology (2020)
The Type2 EWS-Fli1 protein causes a greater up-regulation of elements of the human stromelysin 3 promoter compared with EWS-Fli1 Type 1 and Fli1
Authors: B. S. Ubhi
Journal: Journal of Clinical Oncology (2006)

9538 Background: The role of EWS-Fli1 in the pathogenesis of Ewing’s sarcoma has been extensively investigated. This translocation is found in 85% of Ewing’s tumours. The translocation brings together two genes, EWS and Fli1. EWS is thought to have homology with RNA polymerase whilst Fli1 is a member of the ETS family of transcription factors. The EWS-Fli1 translocation was previously thought to result in an increase in Fli1 activity at target gene promoters including human stromelysin 1. Mutants of the human stromelysin promoter were therefore constructed and cloned into the pGL-3 luciferase reporter vector system and co-transfected with either EWS-Fli1 (type 1 or 2) and/or Fli1 expression vectors. We had previously detemined that EWS-Fli1 appeared to have greater activity at the 5’ end of the stromelysin promoter compared with Fli1.This system was therefore used to investigate the activity of EWS Fli1 type1, Ews-Fli1 type 2 and Fli1 on a 5’ element of the human stromelysin 1 promoter (containing the 5’ 335bp of the promoter). Methods: 1μg of the reporter vector strom-3’Δ5 (containing the 5’ 335bp of the human stromelysin 1 promoter) was co-transfected into NIH3T3 cells with 1μg of the expression vectors ES-TPF10 (EWS-Fli1 Type1),ES-RDP20 (EWS-Fli1 type 2) or Fli1-DH6 (Fli1). The cells were incubated at 37 o C in 5% CO 2 for 24 hours before being lysed and assayed for luciferase activity. Conclusions: Ews-Fli1 (type 1 and 2) caused a higher level of stimulation of this promoter element compared with Fli1. Interestingly, the type 2 translocation caused a significantly higher level of expression of this promoter element compared with type 1, a finding which may reflect the disease pattern observed clinically. [Table: see text] No significant financial relationships to disclose.
THE EFFECT OF FLOW AND GRADIENT ON THE ACCELERATION AND EJECTION TIMES AND THEIR RATIO IN PATIENTS WITH SEVERE AORTIC STENOSIS
Authors: Saba Assar, Ramy Mando, Rick Gaines, George S. Hanzel, Francis Shannon, Ivan Hanson, Wei Lau, Steven Almany, Robert D. Safian, Nathan Kerner, Michael Gallagher, Alessandro Vivacqua, Amr E. Abbas
Journal: Journal of the American College of Cardiology (2020)
Chemotherapy followed by low dose radiotherapy in childhood Hodgkin’s disease. Retrospective analysis of results and prognostic factors
Authors: G. Viani, P. Novaes, J. Salvajoli, R. Ferrigno, C. Pellizzon, R. Fogaroli, M. Maia
Journal: Journal of Clinical Oncology (2006)

9039 Background: To report on treatment results and prognostic factors of young patients with Hodgkin’s disease treated with chemotherapy (CT) followed by low dose radiotherapy (RT). Methods: This retrospective series analysed 166 patients under 18 years old, treated from January 1985 to December 2003. Median age was 10 years (range 2–18). The male to female ratio was 2,3:1. Adenomegalia was the most frequent complaint (68%), and the time of symptom duration was smaller than 6 months in 55% of the patients. In histological analysis Nodular Sclerosis was the most prevalent type (43%) followed by Mixed Celularity (41%). The disease was restricted to two nodal group ( stage II) in 60% and to adjacent groups in 55% (stage III). The most frequent site of metastasis ware the bone marrow (38%) and lungs (42%). Standard treatment consisted of chemotherapy (drug combination varied according to treatment protocols vigent). Radiotherapy consisted of 21 Gy dose in 17 fractions in most part of patients (90.2%), delivered to involved field or mantle field. 13,86% patients did not receive RT. Results: The OS and EFS in 10 years were 88.6% and 82.4%.Survival according to clinical stage as 94.4%, 94.25%, 90.6% and 71.5% for stages I to IV (p=0.0215). The OS in 90.5% of patients who received RT and in 75.6% of patients who did not (p=0.001). Multivariate analysis showed presence of B symptoms and low platelet count to be associated with a worse prognosis. Conclusions: This study shows that combining chemotherapy and low dose RT is an effective treatment for HL in childhood, providing high rates of cure and disease control (88.6% in 10 years), and that so far it is not possible to abdicar RT. And yet, attention to platelet count should be payed in order to improve survival. Also, B symptom presenting children may be involved in more aggressive protocols so survival can be improved. As the disease is highly curable, any data of long term follow-up should be presented in order to better direct therapy, improving outcome and lowering side effects. No significant financial relationships to disclose.
The Added Value of Tau-PET in the Assessment of Progressive Supranuclear Palsy
Authors: Diego Alfonso López-Mora, Alejandro Fernández León, Alberto Lleó, Rafael Blesa, Valle Camacho
Journal: Clinical Nuclear Medicine (2020)

Progressive supranuclear palsy (PSP) is rare neurodegenerative disorder characterized by deposition of fibrillar aggregates of 4R tau-protein in neurons and glial cells. This disorder is underdiagnosed due to the overlap of the clinical syndrome with other related conditions. The clinical manifestations include cognitive impairment associated with behavioral changes, akinetic rigid syndrome, and prominent oculomotor dysfunction. We present the F-FDG and F-THK5351 PET images of a 71-year-old man diagnosed of probable PSP. This image highlights the hopeful results of the new tau-PET ligands radiotracers, because it allows to assess the distribution of tau-protein over time, closely associated with neurodegeneration in PSP.
Phase Ib study of oral PPARγ agonist efatutazone (CS-7017) in combination with erlotinib in Korean patients with metastatic or unresectable locally advanced non-small cell lung cancer (NSCLC) who progressed after first-line therapy.
Authors: Sang-We Kim, Chang-Min Choi, Dae Ho Lee, Jae Cheol Lee, Cheolwon Suh, Jung Shin Lee
Journal: Journal of Clinical Oncology (2012)

e18052 Background: Efatutazone is a novel, third-generation thiazolidinedione (TZD) showing higher potency over second generation TZDs, such as pioglitazone. In non-Asian patients with advanced solid tumors, the recommended dose is 0.50 mg twice-daily (BID) in accordance with PK, PD and safety analyses in a US phase 1 study. This study assessed the safety, tolerability, PK, antitumor activity, PD, and determined the recommended dose of efatutazone in combination with erlotinib in Korean patients. Methods: This was an open-label, dose-escalation study using a 3+3 design in combination with erlotinib. Each patient participated in only 1 dose group and received oral efatutazone 0.25 or 0.50 mg BID with administration of erlotinib 150 mg QD. After determining the recommended dose of efatutazone, 9 additional patients were enrolled to the recommended dose for further assessment. PK samples were collected at day 1 and 22. PD samples were collected weekly until day 36. All subjects provided written informed consent. Results: A total of 14 patients were enrolled (10 male and 4 female; age range: 39–73 years; 12 Adenocarcinoma and 2 Squamous cell carcinoma; EGFR mutation: 5 positive, 4 negative and 5 not conducted) and received treatment at doses of 0.25 and 0.50 mg BID (n= 3 in 0.25mg, n= 11 in 0.50mg cohort). DLT were not observed, and the MTD was not reached. Efatutazone was well tolerated. The majority of patients experienced edema (78.6%, 11 out of 14 patients) and weight increase (64.3%, 9 out of 14 patients), often requiring diuretics. Five out of 14 patients showed PR (3 confirmed in 0.50mg cohort) and 4 patients showed SD. Efatutazone increased plasma adiponectin levels in a dose-dependent manner. Conclusions: Efatutazone is a novel anticancer therapy and in combination with erlotinib was tolerated and demonstrated early evidence of antitumor activity. Although the MTD for efatutazone was not reached, 0.50 mg BID, corresponding to the global recommended dose, was selected as the recommended dose for Korean patients. Full safety data and clinical activity data will be presented.
Long-term central venous catheter use among cancer patients in administrative claims data.
Authors: Allison Nicole Lipitz Snyderman, Kent Sepkowitz, Elena B. Elkin, Laura C Pinheiro, Crystal Son, Peter Bach
Journal: Journal of Clinical Oncology (2012)

6101 Background: This study’s objective was to examine administrative claims data’s capacity to serve as a surveillance tool for long-term catheter use and related bloodstream infections among cancer patients. Population-based estimates and efforts to track catheter use and infections for this group are limited. As such, we sought to explore catheter use documentation using a cohort of colorectal cancer patients. Methods: We performed a retrospective analysis using the population-based SEER-Medicare dataset for patients 66 years or older diagnosed with colorectal cancer in 2005-2007 (n = 54,870). Insertions and removals of long-term central venous catheters (i.e., tunneled, ports/pumps, peripherally inserted central catheter [PICCs]) were identified by billing codes within 2 years of diagnosis. Factors associated with catheter use were identified in multivariable logistic regression analysis. Results: Findings were consistent with clinical expectations. A total of 11,775 patients (21%) had at least one documented long-term catheter insertion within 2 years of diagnosis, 19% within 6 months. Of those with catheters, approximately 25% had more than one insertion. Sixty-eight percent had at least one port/pump, 8% at least one tunneled catheter, and 33% at least one PICC. Seventy-four percent of catheterized patients had IV chemotherapy. Of patients stages I, II, III, and IV, 10%, 18%, 37%, and 39% had catheters, respectively. Adjusted for other factors, patients with catheters were significantly more likely to be younger, female, black (vs. white), and have comorbidities (vs. none documented in year prior to diagnosis), compared to patients without catheters. By the end of the study, 34% of patients with ports/pumps had documented removal and 42% died (for patients with tunneled catheters, 28% and 52%, respectively). Conclusions: Findings support the use of claims data to capture long-term catheter use in cancer patients, providing a foundation for exploration of its capacity to capture infections. Given extensive documented catheter use (21%), infections may be a significant problem. Claims data may offer a low-burden method for surveillance and study, aiding the development of targeted initiatives.
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Authors: Ricardo J. Samms, Matthew P. Coghlan, Kyle W. Sloop
Journal: Trends in Endocrinology and Metabolism (2020)

Glucagon-like peptide-1 (GLP-1) receptor agonists improve glucose homeostasis, reduce bodyweight, and over time benefit cardiovascular health in type 2 diabetes mellitus (T2DM). However, dose-related gastrointestinal effects limit efficacy, and therefore agents possessing GLP-1 pharmacology that can also target alternative pathways may expand the therapeutic index. One approach is to engineer GLP-1 activity into the sequence of glucose-dependent insulinotropic polypeptide (GIP). Although the therapeutic implications of the lipogenic actions of GIP are debated, its ability to improve lipid and glucose metabolism is especially evident when paired with the anorexigenic mechanism of GLP-1. We review the complexity of GIP in regulating adipose tissue function and energy balance in the context of recent findings in T2DM showing that dual GIP/GLP-1 receptor agonist therapy produces profound weight loss, glycemic control, and lipid lowering.
The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: a multicentre prospective observational study
Authors: Y. Fujisawa, T. Fujimura, S. Matsushita, Y. Yamamoto, H. Uchi, A. Otsuka, T. Funakoshi, T. Miyagi, H. Hata, M. Gosho, Y. Kambayashi, M. Aoki, T. Yanagi, A. Ohira, Y. Nakamura, T. Maeda, K. Yoshino
Journal: British Journal of Dermatology (2020)

Taxanes are the current first-line treatment for advanced cutaneous angiosarcoma (CAS) for patients who are considered difficult to treat with doxorubicin owing to advanced age or comorbidity. However, no effective second-line therapy for such patients has been established.We designed a single-arm prospective observational study of eribulin mesylate (ERB) administered at a dose of 1·4 mg m-2 on days 1 and 8 in a 21-day cycle. Patients with advanced CAS who were previously treated with a taxane and were scheduled to begin ERB treatment were enrolled. The primary endpoint was overall survival (OS) and the secondary endpoints were response rate (RR), progression-free survival (PFS) and toxicity assessment.We enrolled a total of 25 patients. The median OS and PFS were 8·6 months and 3·0 months, respectively. The best overall RR was 20% (five of 25). In total, 16 grade 3/4 severe adverse events (SAEs) occurred; however, all patients recovered. Patients who achieved partial response or stable disease as best response had longer OS than those with progressive disease (median OS not reached and 3·3 months, respectively; P < 0·001). Patients who did not experience SAEs showed longer OS than those who did (median OS 18·8 months and 7·5 months, respectively; P < 0·05). Patients with distant metastasis had shorter median OS than those with locoregional disease, but without statistically significant difference.ERB showed a promising RR and is a potential candidate for second-line treatment for patients with CAS, after treatment with taxanes. However, owing to the occurrence of SAEs in over half of the participants, caution should be exercised regarding ERB use in elderly patients. What is already known about this topic? Taxanes are the current first-line treatment for patients with advanced cutaneous angiosarcoma (CAS) who are considered difficult to treat with doxorubicin owing to advanced age or comorbidity. No effective therapy for taxane-resistant CAS has been established thus far. Eribulin suppresses microtubule polymerization and elicits an antitumour effect similar to that of taxanes. What does this study add? In our single-arm prospective observational study to evaluate the efficacy of eribulin for treating patients with advanced CAS who previously received taxanes, the median overall survival and progression-free survival were 8·6 and 3·0 months, respectively. Response rates at weeks 7, 13 and 25 were 20%, 17% and 14%, respectively. Although 16 grade 3/4 severe adverse events occurred, all patients recovered. Eribulin showed a promising response rate and is a potential candidate for second-line treatment in CAS after taxane treatment. Linked Comment: Smrke and Benson. Br J Dermatol 2020; 183:797-798.
SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes
Authors: Waradon Sungnak, Ni Huang, Christophe Bécavin, Marijn Berg, Rachel Queen, Monika Litvinukova, Carlos Talavera-López, Henrike Maatz, Daniel Reichart, Fotios Sampaziotis, Kaylee B. Worlock, Masahiro Yoshida, Josephine L. Barnes
Journal: Nature Medicine (2020)